X @The Wall Street Journal

Chief Executive Mike Hsu’s $40 billion deal for Tylenol maker Kenvue aims to stoke Kimberly-Clark's growth by veering into Kenvue’s higher-margin but risky health products https://t.co/IszI0reBKQ ...